Lactylation-Driven NSUN2 m5C Modification Fuels Neural Invasion in PDAC

Study Background and Research Question

Perineural invasion (PNI) is a hallmark of pancreatic ductal adenocarcinoma (PDAC), closely linked to its high malignancy, local dissemination, and poor prognosis. Clinically, PNI is observed in up to 80–100% of PDAC cases and is a strong predictor of early relapse and reduced survival. While the multifaceted tumor microenvironment of PDAC is known to promote such aggressive features, the molecular mechanisms connecting metabolic stress to neural invasion remain incompletely understood. Lysine lactylation (Kla), a post-translational modification induced by elevated lactate, has emerged as a regulatory node in several cellular processes, yet its role in PDAC progression and PNI is only beginning to be elucidated. The RNA methyltransferase NSUN2, responsible for 5-methylcytosine (m5C) modification on RNA, is implicated in cancer invasion and metastasis. However, how NSUN2 activity is modulated by metabolic cues and whether this axis contributes to PNI in PDAC had not been fully explored prior to this study.

Key Innovation from the Reference Study

The referenced study (Theranostics 2026) makes a pivotal discovery: metabolic stress, via increased lactate levels, drives lysine 692 lactylation of NSUN2. This lactylation stabilizes NSUN2 by preventing its ubiquitin-mediated degradation, thereby enhancing its function as an m5C RNA methyltransferase. The stabilized, lactylated NSUN2 modifies specific pro-invasive transcripts (notably CDCP1 and STC1), increasing their mRNA stability and promoting neural invasion. This lactate–NSUN2–m5C–CDCP1/STC1 axis is shown to drive PNI in PDAC, providing a direct molecular bridge between metabolic reprogramming and invasive tumor behavior. The identification of NSUN2 K692 lactylation as a modifiable driver of PNI uncovers a new therapeutic vulnerability in one of the most lethal human malignancies.

Methods and Experimental Design Insights

The investigators employed an integrative approach spanning human cohort analysis, in vitro mechanistic studies, and in vivo validation. Key methodologies include:

• Clinical correlation: Assessment of lactate, pan-lactylation, and NSUN2 lactylation levels in human PDAC samples, coupled with PNI scoring and survival analysis.
• Cellular assays: Functional studies using PDAC cell lines evaluated migration, invasion, and interaction with dorsal root ganglion (DRG) neurons. Neurite outgrowth assays were performed under conditions of elevated lactate or with enzymatic modulation of lactylation.
• Genetic manipulation: CRISPR-Cas9-mediated NSUN2 knockout, along with generation of K692R/K692E point mutants, allowed direct probing of lactylation effects.
• RNA-protein interaction and modification mapping: Co-immunoprecipitation, RNA immunoprecipitation sequencing (RIP-seq), m5C RNA immunoprecipitation-qPCR (MeRIP-qPCR), and actinomycin D chase assays were used to identify m5C-modified targets and assess mRNA stability.
• In vivo models: Sciatic nerve invasion models and KPC (Kras^G12D/Trp53^R172H;Pdx1-Cre) genetically engineered mice provided platforms to observe tumor-nerve infiltration and overall disease progression.

Core Findings and Why They Matter

Major observations from the study include:

• Correlation with prognosis: High levels of lactylated NSUN2 in both human and murine PDAC are associated with severe PNI and reduced survival.
• Lactylation controls NSUN2 stability: Lactate-induced K692 lactylation inhibits NSUN2 ubiquitination, preventing its degradation and enhancing overall protein abundance.
• Epitranscriptomic regulation: Lactylated NSUN2 mediates m5C modification of CDCP1 and STC1 mRNAs, leading to their stabilization. These transcripts are known to promote tumor invasion and neural interaction.
• Functional consequence: Disruption of NSUN2, inhibition of lactylation, or mutation of K692 markedly impairs PDAC cell invasion, migration, and tumor-nerve interaction in vitro, and attenuates PNI and disease progression in vivo.

Collectively, these findings elucidate a direct, mechanistically supported pathway by which metabolic stress rewires the epitranscriptome to enable neural invasion—a process central to the lethality of PDAC. By identifying actionable nodes (e.g., NSUN2 lactylation), the study opens new avenues for targeted therapy in aggressive pancreatic cancer subtypes.

Comparison with Existing Internal Articles

Although the molecular focus of this study lies in the cancer biology domain, mechanistic parallels can be drawn with research tools and workflows established in nephrology, particularly those employing the aminonucleoside moiety of puromycin. For instance, internal reviews discuss how puromycin aminonucleoside is leveraged to model podocyte injury in nephrotic syndrome research, relying on well-defined toxic mechanisms and cytoskeletal disruption. In both contexts—renal disease and PDAC—there is an emphasis on specific post-translational and epitranscriptomic modifications (such as methylation, lactylation, or cytoskeletal perturbation) as drivers of cellular fate and disease progression.

Articles such as "Puromycin aminonucleoside: Precise Tool for Podocyte Injury Models" illustrate how the aminonucleoside moiety of puromycin provides a reproducible model for studying proteinuria and glomerular lesion induction in animal systems. While the disease models differ, the strategy of using metabolic or chemical perturbation to unravel molecular underpinnings—exemplified here by lactylation and m5C modification in PDAC—reflects a convergent workflow in experimental biology.

Limitations and Transferability

Despite its comprehensive design, the study has several limitations:

• Model specificity: The findings are validated largely in PDAC models and may not directly extrapolate to other tumor types or non-malignant neural invasion processes.
• Metabolic context: The extent to which lactate-driven post-translational modifications operate in the broader tumor microenvironment, beyond the models tested, remains to be determined.
• Therapeutic translation: While actionable targets are identified, the safety and efficacy of direct NSUN2 or lactylation inhibition in clinical settings require further investigation.

Nonetheless, the study's mechanistic rigor and translational focus make it a valuable foundation for future preclinical and early-phase clinical research into neural invasion and metabolic-epigenetic crosstalk in cancer.

Protocol Parameters

• Lactate induction: PDAC cell lines were exposed to elevated extracellular lactate (concentration range and duration optimized per cell line) to induce lysine lactylation.
• CRISPR mutagenesis: NSUN2 K692R/E point mutations were generated using sgRNA/Cas9 delivery and validated by sequencing.
• Neurite outgrowth assays: DRG neurons were co-cultured with PDAC cells under defined lactate conditions; neurite length changes quantified by immunofluorescence microscopy.
• Actinomycin D chase: mRNA stability was measured following transcriptional blockade (typically 5 μg/mL ActD) with time-course sampling for qPCR.
• Sciatic nerve invasion model: Tumor cells were orthotopically implanted near the sciatic nerve in mice; PNI monitored by histology and behavioral assessment.

Research Support Resources

For researchers aiming to model cell injury, cytoskeletal disruption, or metabolic-epigenetic regulation, tools such as Puromycin aminonucleoside (SKU A3740) are available for the induction of proteinuria and glomerular lesions in animal models. The aminonucleoside moiety of puromycin is widely used to create robust podocyte injury models and investigate the molecular basis of cell injury and nephrotic syndrome, as summarized in recent methodological articles. Detailed solubility and handling protocols are provided to support experimental reproducibility. While the principal focus of the present study is on lactylation and RNA modification in cancer, the integration of metabolic modulators and injury models remains a cornerstone of mechanistic biomedical research.